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Background
Allergen immunotherapy (IT) is widely used to treat
patients with allergic diseases, proven effective and
recommended by national and international guidelines.
Its efficacy and safety depend on the correct indication,
use of relevant allergens and good quality extracts, as
well as prescription and supervision by a trained profes-
sional. Our aims were to evaluate the frequency of use
of IT in Brazil and to investigate whether this practice
meets recommendations of the Brazilian Association of
Allergy and Immunology (ASBAI) and Brazilian Medical
Association.
Methods
Standardized questionnaire consisting of 20 items was
applied to physicians participating in the annual congress
of ASBAI. The questionnaire was anonymous and volun-
tary, and evaluated data related to medical training,
board certification, duration of professional practice,
indications for IT, age limitation, mode of administration
and schedules, type and standardization of extracts, dura-
tion of IT and administration site.
Results
Four-hundred twenty two questionnaires were com-
pleted; 88.2% of participating professionals reported
training in Allergy and Immunology, and 57.8% were
Board certified in Allergy and Immunology. Sixty-eight
percent practice the specialty >5 years; 79.2% work in pri-
vate practice and 80.6% perform IT in clinical practice.
Among IT prescribers, 121 (35.6%) are not Board certi-
fied by ASBAI. IT is used most often with the following
indications: rhinoconjunctivitis - 97.9%, cutaneous
reactions to mosquito bites - 75.1%, asthma - 72.2%, ato-
pic dermatitis - 57.4%, allergy to insect stings - 52.1% and
food allergy - 7.9%. The data revealed that 75.6% of pro-
fessionals prescribe IT for children <5 years and 48.2%
for patients> 65 years. Mode of IT included SCIT -
91.7%; SLIT - 52.9%; SCIT rush - 7.1% and oral desensiti-
zation - 10.9%. The duration of IT was: <3 years - 38.7%,
3-5 years - 58% and> 5 years - 1.2%. IT is conducted in
health care units in 88.1% of cases.
Conclusions
Both SCIT and SLIT are widely used in Brazil. Most
professionals who use IT have training in Allergy and
Immunology (88.2%), however, only 57.8% are Board
certified. The practice of IT occurs predominantly in
private clinics. A significant percentage of physicians
perform practices which are not in full agreement with
national and international recommendations, including
prescription of IT for children <5 years and patients >
65 years, and duration of IT less than 3 years in 38.7%
of cases.
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